"If approved by the U.S. Food and Drug Administration (FDA), the market for ADLS' drug candidate Cethromycin could reach more than $1 billion at its market saturation. Cethromycin has cleared phase III clinical trials, with the prospects of reaching commercialization reaching approximately 90% following final approval from the FDA."